CGG Awarded Exclusive Contract to Provide HPC Cloud Solutions to Biosimulytics for AI-powered Drug Development
04 Mai 2023 - 07:30AM
GlobeNewswire Inc.
CGG Awarded Exclusive Contract to Provide HPC Cloud Solutions to
Biosimulytics for AI-powered Drug Development
Paris, France – May 4, 2023
CGG, a global technology and HPC leader, has
signed a contract to be the exclusive HPC cloud partner of
Biosimulytics, an Irish pharma software company that uses
artificial intelligence (AI) to dramatically improve the speed,
cost, novelty and success rate in new drug development.
CGG will be providing Biosimulytics with a fully
customized HPC (high-performance computing), AI and cloud solution.
Using CGG’s algorithm and HPC expertise enables Biosimulytics to
fully scale their breakthrough pharmatech platform which provides
pharmaceutical companies worldwide with a powerful predictive
simulation capability when developing new drug molecules. Their
innovative approach shortens the time to market and reduces the
risks for important developments in the pharmaceutical industry in
getting from molecules to medicine (M2M) and is a key enabling
technology for the new era of precision medicine.
CGG’s custom solution meets the specialist needs
of Biosimulytics for a high-performing HPC and AI environment that
optimizes its suite of specialized molecular simulation
applications from crystal structure prediction (CSP) to
structure-based drug design (SBDD). Biosimulytics can now run
applications at least five times faster than its previous public
cloud solution, enabling it to dramatically improve its return on
investment and expand its business. As a European company offering
cloud services hosted in the European Union, CGG also offers the
full legal protection of EU regulations for the intellectual
property of Biosimulytics and its customers.
Biosimulytics, which is headquartered at NovaUCD
in Dublin, is a University College Dublin (UCD) spin-out company
that is strongly backed at national and European levels and is
working as a Digital R&D solution provider to some of the
world’s leading pharmaceutical companies.
Peter Doyle, CEO, Biosimulytics, said, “We are
delighted to announce this exclusive partnership with CGG since our
need for a high-performing HPC and AI environment to optimize our
Biosim M2M platform is uniquely met with CGG's customized solution.
The AI drug development space is now at an inflection point and the
market is expected to exceed US$10bn by 2030 growing at a CAGR of
25%. Our ambition is to enable the global pharma industry to
advance potential molecules to approved medicines quicker and with
a much greater probability of success by making AI-powered
predictive technology much more accessible and affordable for
widespread use by everyone from Big Pharma to small emerging
biotech companies. Today’s announcement with CGG is a significant
milestone on that journey.”
Agnès Boudot, EVP, HPC & Cloud Solutions,
CGG, said: “CGG is a global expert in industrial and customized
end-to-end HPC and AI services with over 70 years of experience in
pioneering computing solutions. After successfully establishing our
cloud services offering in the energy, energy transition and mining
sectors, where more than 30 external clients are currently directly
accessing and using CGG Cloud solution services for delivering
insights into their data, we are pleased to expand into the
healthcare and life sciences market by supporting Biosimulytics in
using AI- and HPC-based technologies to help unlock new and
improved therapies faster and more cost efficiently. Our experience
of hosting and optimizing scientific workflows running on over 350
petaflops at an industrial scale ensures that we can provide
Biosimulytics with a scalable solution to meet their future growth
requirements for this complex HPC and AI workflow.”
About CGG
CGG (www.cgg.com) is a global technology and HPC
leader that provides data, products, services and solutions in
Earth science, data science, sensing and monitoring. Our unique
portfolio supports our clients in efficiently and responsibly
solving complex digital, energy transition, natural resource,
environmental, and infrastructure challenges for a more sustainable
future. CGG employs around 3,400 people worldwide and is listed on
the Euronext Paris SA (ISIN: 0013181864).
Contacts
Group Communications & Investor Relations
Christophe BarniniTel: + 33 1 64 47 38 11E-Mail:
christophe.barnini@cgg.com |
|
P
- CGG Awarded Contract HPC Biosimultics
CGG (EU:CGG)
Graphique Historique de l'Action
De Août 2023 à Sept 2023
CGG (EU:CGG)
Graphique Historique de l'Action
De Sept 2022 à Sept 2023